You are here: Industry Insights > Lantus

News List

FDA approves first interchangeable biosimilar insulin product europeanpharmaceuticalreview
July 30, 2021
The first interchangeable biosimilar insulin product will help increase access and affordability of insulin for diabetics.
FDA Approves Biosimilar Interchangeable Insulin Treatment for Diabetes americanpharmaceuticalreview
July 30, 2021
The FDA approved the first interchangeable biosimilar product, Mylan’s Semglee (insulin glargine-yfgn). Semglee (insulin glargine-yfgn) is both biosimilar to and interchangeable with Lantus (insulin glargine).
Which Blood Sugar Meds Work Best Against Type 2 Diabetes? drugs
June 30, 2021
You have type 2 diabetes, and you are already taking an old standby drug, metformin. But you still need help controlling your blood sugar levels.
Mylan, Biocon Biologics Announce Launch of Semglee in U.S. americanpharmaceuticalreview
September 01, 2020
Mylan and Biocon Biologics India announced the U.S. launch of Semglee™ (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with...
Biocon’s partner Mylan receives favourable ruling from US PTAB on Sanofi’s four device patents for L expresspharma
June 02, 2020
Reportedly, the PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.
Mylan announces victory over Sanofi in Lantus patent claims pharmaceutical-technology
December 17, 2018
Generic drug maker Mylan has announced that the US Patent and Trademark Appeal Board (PTAB) invalidated Sanofi’s patent infringement claims over insulin drug Lantus......
Mylan says Sanofi loses Lantus insulin patent claims expressbpd
December 14, 2018
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar
US Patent Office Rules Sanofi's Formulation Patents on Multibillion-Dollar Lantus Invalid americanpharmaceuticalreview
December 14, 2018
Mylan announced the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and .....
GC pharma announces approval for Lantus biosimilar in Korea biospectrumasia
March 15, 2018
The company plans to launch Glarzia Prefilled Pen, a Lantus biosimilar developed by Indian drug maker Biocon, in the third quarter this year
Sanofi files suit in the US to defend its patent rights on Lantus cphi-online
August 11, 2017
Sanofi has filed a patent infringement suit to claims two patent rights on Lantus against Merck.